ACAD - ACADIA Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
300,321
223,807
124,901
17,331
61
Cost of Revenue
17,087
12,377
9,077
3,075
0
Gross Profit
283,234
211,430
115,824
14,256
61
Operating Expenses
Research Development
231,048
187,163
149,189
99,284
73,869
Selling General and Administrative
309,607
271,711
259,045
187,787
90,804
Total Operating Expenses
540,655
458,874
408,234
287,071
164,673
Operating Income or Loss
-257,421
-247,444
-292,410
-272,815
-164,612
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
633
-1,840
-
0
0
Income Before Tax
-247,225
-243,936
-288,284
-270,052
-164,113
Income Tax Expense
490
1,256
1,119
1,341
330
Income from Continuing Operations
-247,715
-245,192
-289,403
-271,393
-164,443
Net Income
-247,715
-245,192
-289,403
-271,393
-164,443
Net Income available to common shareholders
-247,715
-245,192
-289,403
-271,393
-164,443
Reported EPS
Basic
-
-1.94
-2.36
-2.34
-1.63
Diluted
-
-1.94
-2.36
-2.34
-1.63
Weighted average shares outstanding
Basic
-
126,583
122,600
115,858
100,630
Diluted
-
126,583
122,600
115,858
100,630
EBITDA
-
-244,439
-289,697
-270,987
-164,612